Quick Answer
XBiotech Inc. reported R&D Expense of $47.39 million for fiscal year 2025.
XBiotech Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $47.39M | +25.5% |
| 2024 | $37.76M | +14.9% |
| 2023 | $32.85M | +4.1% |
| 2022 | $31.54M | +11.6% |
| 2021 | $28.27M | +196.7% |
| 2020 | $9.53M | -60.5% |
| 2019 | $24.09M | +53.2% |
| 2018 | $15.72M | -40.5% |
| 2017 | $26.42M | -37.8% |
| 2016 | $42.49M | +35.7% |
| 2015 | $31.31M | +118.5% |
| 2014 | $14.33M | +80.6% |
| 2013 | $7.93M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.08M | -28.7% | -4.8% |
| June 30, 2025 | $5.34M | -58.9% | -54.1% |
| March 31, 2025 | $11.62M | +18.3% | +63.0% |
| September 30, 2024 | $7.13M | -5.6% | -45.1% |
| June 30, 2024 | $12.98M | +15.2% | +32.2% |
| March 31, 2024 | $9.82M | +57.7% | +30.2% |
| September 30, 2023 | $7.55M | +7.6% | -33.0% |
| June 30, 2023 | $11.27M | +8.4% | +80.8% |
- XBiotech Inc. showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, XBiotech Inc.’s r&d expense has grown by 497.2% (from $7.93 million to $47.39 million).
- The most recent figure is from XBiotech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: